KMDA - FDA updates EUA for COVID convalescent plasma limiting use to certain patients

The FDA has updated the Emergency Use Authorization ("EUA") for the use of convalescent plasma as a COVID-19 treatment for patients with immunosuppressive disease or receiving immunosuppressive treatment. The FDA reiterated that the plasma product used must have high titers of anti-SARS-CoV-2 antibodies. The FDA first issued the EUA in August 2020. Convalescent plasma players: Kamada (NASDAQ:KMDA), Grifols (NASDAQ:GRFS), XBiotech (NASDAQ:XBIT), Cerus (NASDAQ:CERS), and ADMA Biologics (NASDAQ:ADMA). Dear readers: We recognize that politics often intersects with the financial news of the day, so we invite you to click here to join the separate political discussion.

For further details see:

FDA updates EUA for COVID convalescent plasma limiting use to certain patients